Laobaixing released its 2026 interim report on August 28, 2026. During the reporting period, the company achieved total operating revenue of 10.998 billion yuan and net profit attributable to the parent of 447 million yuan. Net cash inflow from operating activities was 1.404 billion yuan, a decrease of 222 million yuan compared with the same period last year, down 13.66 percent year on year. The company's asset-liability ratio was 60.55 percent, ranking 14th among peer companies that have disclosed data. Gross margin was 32.45 percent, down 1.06 percentage points from the previous quarter and down 0.63 percentage points from the same period last year. Return on equity was 6.40 percent. Diluted earnings per share were 0.59 yuan. Total asset turnover was 0.57 times, and inventory turnover was 2.08 times, ranking 17th among peer companies that have disclosed data. The company had 58,500 shareholders, and the top ten shareholders held 398 million shares, accounting for 52.46 percent of total share capital.
Laobaixing PharmacyInterim report shows net profit of 447 million yuan, but revenue and cash flow details are mixed, with no clear positive or negative signal.